Lv2
128 积分 2024-03-18 加入
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
21小时前
待确认
Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
3个月前
已完结
In vivo CAR T cell generation to treat cancer and autoimmune disease
5个月前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
5个月前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
6个月前
已完结
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
6个月前
已完结
Engineering sonogenetic EchoBack-CAR T cells
8个月前
已完结
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
8个月前
已完结
Noncoding regions are the main source of targetable tumor-specific antigens
10个月前
已完结
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
10个月前
已完结
皖公网安备34019202002308
